<DOC>
	<DOC>NCT00320515</DOC>
	<brief_summary>This is a multicenter, single arm, open-label Phase 1/2 study of pemetrexed plus cisplatin for patients with unresectable, advanced gastric cancer who had no prior palliative chemotherapy. Phase 1 was designed to determine the optimal dose of pemetrexed for its phase 2, which has been completed and now a total of 60 qualified patients will be enrolled in the phase 2 of this study. The treating physician will determined the maximum number of cycles of pemetrexed plus cisplatin that a patient may receive in this study.</brief_summary>
	<brief_title>Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histological proven diagnosis of adenocarcinoma of the stomach Stage IV disease not amenable to curative surgery. Disease status must be that of measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale. Adequate organ functions Prior palliative chemotherapy for advanced gastric cancer. Pregnancy and breast feeding. Known or suspected brain metastasis and secondary primary malignancy Inability to interrupt aspirin, or other nonsteroidal antiinflammatory agents for a 5day period. Inability or unwillingness to take folic acid or vitamin B12 supplementation. Concurrent administration of any other tumor therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>